or Try an Advanced Search...

    Technical Analysis for TRVN - Trevena, Inc.

    Grade Last Price % Change Price Change
    F 0.43 -3.18% -0.01
    TRVN closed down 3.18 percent on Wednesday, May 8, 2024, on 23 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: May 13
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical TRVN trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Weak + Overbought Other 0.00%
    Inside Day Range Contraction 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Pocket Pivot Bullish Swing Setup -3.18%
    Doji - Bearish? Reversal -3.18%
    Stochastic Reached Overbought Strength -3.18%
    Weak + Overbought Other -3.18%
    Older End-of-Day Signals for TRVN ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 19 hours ago
    Down 3% about 23 hours ago
    Down 2 % about 23 hours ago
    Down 1% about 23 hours ago
    Fell Below Upper Bollinger Band about 23 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    TRVN Chart by TradingView
    Basic chart:

    Profile

    Trevena, Inc. Description

    Trevena, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing therapeutics for G protein coupled receptors. Its products include TRV027 that has completed Phase 2a clinical trials for the treatment of acute heart failure; TRV130, a small molecule G protein biased ligand at the µ-opioid receptor has completed Phase 1b clinical trials to treat moderate to severe acute pain intravenously; TRV734 that is in preclinical studies as a orally administered treatment of moderate to severe acute and chronic pain; and d-opioid receptor G protein biased ligand therapeutics for the treatment of central nervous system disorders. The company was formerly known as Parallax Therapeutics, Inc. and changed its name to Trevena, Inc. in January 2008. Trevena, Inc. was founded in 2007 and is based in King of Prussia, Pennsylvania.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Pain Organic Compounds Opioids Chronic Pain Heart Failure Central Nervous System Disorders Nervous System Disorders Signal Transduction Analgesics Acute Pain Pyridines Cell Signaling Acute And Chronic Pain Treatment Of Central Nervous System Disorders Opioid Receptors

    Is TRVN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 1 Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
    Jan 10 Trevena files to sell 2.78M shares for holders
    Dec 28 Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
    Dec 27 Trevena announces private placement and warrant exercise
    Dec 27 Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
    Dec 1 Trevena files for $200M mixed shelf
    Nov 30 Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
    Nov 17 Trevena Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
    Nov 15 Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript
    Nov 14 Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
    See more TRVN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.72
    52 Week Low 0.3001
    Average Volume 218,380
    200-Day Moving Average 0.63
    50-Day Moving Average 0.46
    20-Day Moving Average 0.40
    10-Day Moving Average 0.41
    Average True Range 0.04
    RSI (14) 51.69
    ADX 25.49
    +DI 19.84
    -DI 13.94
    Chandelier Exit (Long, 3 ATRs) 0.33
    Chandelier Exit (Short, 3 ATRs) 0.44
    Upper Bollinger Bands 0.44
    Lower Bollinger Band 0.36
    Percent B (%b) 0.86
    BandWidth 20.74
    MACD Line -0.01
    MACD Signal Line -0.02
    MACD Histogram 0.0103
    Fundamentals Value
    Market Cap 7.37 Million
    Num Shares 17.3 Million
    EPS -2.64
    Price-to-Earnings (P/E) Ratio -0.16
    Price-to-Sales 3.16
    Price-to-Book 2.85
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.46
    Resistance 3 (R3) 0.46 0.45 0.45
    Resistance 2 (R2) 0.45 0.44 0.45 0.45
    Resistance 1 (R1) 0.44 0.44 0.43 0.44 0.45
    Pivot Point 0.43 0.43 0.43 0.43 0.43
    Support 1 (S1) 0.42 0.42 0.41 0.42 0.40
    Support 2 (S2) 0.41 0.42 0.41 0.40
    Support 3 (S3) 0.40 0.41 0.40
    Support 4 (S4) 0.40